{"entity":{"id":"nct05027776","kind":"trial","name":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","aka":[],"tldr":"A phase 3 trial of 2-doses Group among 9-14 years in cervical cancer and vaginal cancer, run by Shanghai Bovax Biotechnology Co., Ltd., now recruiting.","summary":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years is a phase 3 interventional study registered as NCT05027776 by Shanghai Bovax Biotechnology Co., Ltd., with 1348 participants planned, started 2021-09-15 and due to reach its primary completion in 2023-11-22. Interventions recorded: 2-doses Group among 9-14 years, 3-doses Group among 9-19 years and 3-doses Group among 20-26 years.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05027776","url":"https://clinicaltrials.gov/study/NCT05027776"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cervical","vaginal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05027776","phase":"3","setting":"Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A Phase 3, Open-label, Non-randomized Clinical Trial","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","enrolled":1348,"outcomes":[]},"route":"/trials/nct05027776/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"vaginal","kind":"cancer","name":"Vaginal cancer","route":"/cancers/vaginal/"}]}}